Escalade (ESCA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for May 6, 2025, to elect five directors, ratify the appointment of Grant Thornton, LLP as auditor, approve executive compensation by non-binding vote, and determine the frequency of future say-on-pay votes.
Proxy materials distributed to shareholders, with voting available by mail, phone, or online.
All directors attended 2024 meetings; three are independent, and two are executive officers.
Voting matters and shareholder proposals
Shareholders will vote on electing five directors, ratifying Grant Thornton, LLP as auditor, approving executive compensation, and setting the frequency of future say-on-pay votes.
Board recommends voting for all director nominees, for auditor ratification, for executive compensation, and for annual say-on-pay votes.
No other shareholder proposals or nominations were received for this meeting.
Proposals for the 2026 meeting must be received by February 4, 2026.
Board of directors and corporate governance
Board consists of five members: three independent and two executive officers.
Board committees: Audit, Compensation, and Nominating & Corporate Governance, all composed of independent directors.
Board diversity policy ensures consideration of women and minority candidates for director roles.
Board leadership structure includes a Chairman (CEO) and a Lead Independent Director.
Directors receive annual retainers, committee fees, and restricted stock units; compensation increased for 2025.
Latest events from Escalade
- Q2 2026 net income surged on $10.2M tariff recovery, with sales and margins rising.ESCA
Q2 2026 - Gross margin and net income surged in Q1 2026, with strong cash flow and prudent capital management.ESCA
Q1 2026 - Proxy covers director elections, auditor ratification, and executive pay, emphasizing governance.ESCA
Proxy filing - Gross margin and net income rose despite lower sales, with net leverage reduced to 0.3x EBITDA.ESCA
Q4 2025 - Sales fell 13.1% year-over-year, but gross margin and balance sheet strength improved.ESCA
Q2 2025 - Q3 net income rose 33% to $5.7M on margin gains and debt reduction despite a 7.7% sales drop.ESCA
Q3 2024 - Q2 sales fell 7.7%, but strong cash flow enabled debt reduction and margin focus.ESCA
Q2 2024 - Net income up 47% on higher margins despite 3.2% sales drop; debt and costs down.ESCA
Q1 2025 - Margin and profitability improved despite lower sales, with strong cash flow and capital returns.ESCA
Q4 2024